Study Graphic

Study number: C2431001

You may qualify to participate if you are:

  • a healthy male or female (unable to bear children) 18-55 years of age.
  • able to meet all eligibility criteria.
  • able to comply with all study visits.

Compensation: You will be compensated for your time up to $2050.00 for completion of the study.

The Pfizer New Haven Clinical Research Unit is conducting a study of a marketed drug, Naloxone hydrochloride (HCl), used in an emergency for the treatment of a narcotic overdose.  It helps to reverse the effects of an overdose, including breathing difficulties.

This study involves: You will be in this study up to about 41 days.  This does not include the time between screening and dosing, which can be up to 28 days.

  • 3 dosing periods (during one continuous admission)
  • 6 overnight stays
  • 1 follow-up phone call (between 28 and 35 days after the last dose)

Please review the informed consent document: C2431001 ICD IRB approved v12Oct2020